Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity

Hagai Tavori, Alexandra M. Fenton, Deanna L. Plubell, Sara Rosario, Elisabeth Yerkes, Rayna Gasik, Joshua Miles, Paige Bergstrom, Jessica Minnier, Sergio Fazio, Nathalie Pamir

Research output: Contribution to journalArticle

Abstract

CONTEXT: Elevated serum lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular disease risk. ABCA1-mediated cholesterol efflux from macrophages may be an antiatherogenic process. Plasminogen (PLG) is a driver of ABCA1-mediated cholesterol efflux, and its action is inhibited by purified human Lp(a). OBJECTIVE: To determine the effects of Lp(a) in human serum on ABCA1 cholesterol efflux. METHODS: Cholesterol efflux capacity (CEC) was measured with two different cell-culture models using serum from 76 patients with either low (<50 mg/dL) or high (>50 mg/dL) Lp(a) levels. RESULTS: Using cAMP-stimulated J774 macrophages or baby hamster kidney fibroblasts overexpressing human ABCA1, we show that CEC was lower in patients with high Lp(a) levels compared with patients with low levels (-30.6%, P = 0.002 vs -24.1%, P < 0.001, respectively). Total-serum CEC negatively correlated with Lp(a) levels (r = -0.433, P = 0.0007 vs r = -0.505, P = 0.0011, respectively). These negative associations persisted after adjusting for serum cholesterol, age, sex, and statin use in a multiple linear regression model (adjusted R2 = 0.413 or 0.405, respectively) and were strengthened when further adjusting for the interaction between Lp(a) and PLG levels (adjusted R2 = 0.465 and 0.409, respectively). Total-serum and isolated Lp(a) from patients with high Lp(a) inhibited PLG-mediated ABCA1 cholesterol efflux. CONCLUSION: Total-serum CEC is reduced in patients with high Lp(a) levels. This is in part due to the inhibition of PLG-mediated ABCA1 cholesterol efflux by Lp(a). Our findings suggest an atherogenic role for Lp(a) through its ability to inhibit CEC.

Original languageEnglish (US)
Pages (from-to)4793-4803
Number of pages11
JournalThe Journal of clinical endocrinology and metabolism
Volume104
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Lipoprotein(a)
Cholesterol
Plasminogen
Serum
Macrophages
Linear Models
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fibroblasts
Cell culture
Linear regression
Cricetinae
Cardiovascular Diseases
Cell Culture Techniques

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity. / Tavori, Hagai; Fenton, Alexandra M.; Plubell, Deanna L.; Rosario, Sara; Yerkes, Elisabeth; Gasik, Rayna; Miles, Joshua; Bergstrom, Paige; Minnier, Jessica; Fazio, Sergio; Pamir, Nathalie.

In: The Journal of clinical endocrinology and metabolism, Vol. 104, No. 10, 01.10.2019, p. 4793-4803.

Research output: Contribution to journalArticle

Tavori, Hagai ; Fenton, Alexandra M. ; Plubell, Deanna L. ; Rosario, Sara ; Yerkes, Elisabeth ; Gasik, Rayna ; Miles, Joshua ; Bergstrom, Paige ; Minnier, Jessica ; Fazio, Sergio ; Pamir, Nathalie. / Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity. In: The Journal of clinical endocrinology and metabolism. 2019 ; Vol. 104, No. 10. pp. 4793-4803.
@article{90e9df5ff3a0453ba73ee84f615af456,
title = "Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity",
abstract = "CONTEXT: Elevated serum lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular disease risk. ABCA1-mediated cholesterol efflux from macrophages may be an antiatherogenic process. Plasminogen (PLG) is a driver of ABCA1-mediated cholesterol efflux, and its action is inhibited by purified human Lp(a). OBJECTIVE: To determine the effects of Lp(a) in human serum on ABCA1 cholesterol efflux. METHODS: Cholesterol efflux capacity (CEC) was measured with two different cell-culture models using serum from 76 patients with either low (<50 mg/dL) or high (>50 mg/dL) Lp(a) levels. RESULTS: Using cAMP-stimulated J774 macrophages or baby hamster kidney fibroblasts overexpressing human ABCA1, we show that CEC was lower in patients with high Lp(a) levels compared with patients with low levels (-30.6{\%}, P = 0.002 vs -24.1{\%}, P < 0.001, respectively). Total-serum CEC negatively correlated with Lp(a) levels (r = -0.433, P = 0.0007 vs r = -0.505, P = 0.0011, respectively). These negative associations persisted after adjusting for serum cholesterol, age, sex, and statin use in a multiple linear regression model (adjusted R2 = 0.413 or 0.405, respectively) and were strengthened when further adjusting for the interaction between Lp(a) and PLG levels (adjusted R2 = 0.465 and 0.409, respectively). Total-serum and isolated Lp(a) from patients with high Lp(a) inhibited PLG-mediated ABCA1 cholesterol efflux. CONCLUSION: Total-serum CEC is reduced in patients with high Lp(a) levels. This is in part due to the inhibition of PLG-mediated ABCA1 cholesterol efflux by Lp(a). Our findings suggest an atherogenic role for Lp(a) through its ability to inhibit CEC.",
author = "Hagai Tavori and Fenton, {Alexandra M.} and Plubell, {Deanna L.} and Sara Rosario and Elisabeth Yerkes and Rayna Gasik and Joshua Miles and Paige Bergstrom and Jessica Minnier and Sergio Fazio and Nathalie Pamir",
year = "2019",
month = "10",
day = "1",
doi = "10.1210/jc.2018-02708",
language = "English (US)",
volume = "104",
pages = "4793--4803",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity

AU - Tavori, Hagai

AU - Fenton, Alexandra M.

AU - Plubell, Deanna L.

AU - Rosario, Sara

AU - Yerkes, Elisabeth

AU - Gasik, Rayna

AU - Miles, Joshua

AU - Bergstrom, Paige

AU - Minnier, Jessica

AU - Fazio, Sergio

AU - Pamir, Nathalie

PY - 2019/10/1

Y1 - 2019/10/1

N2 - CONTEXT: Elevated serum lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular disease risk. ABCA1-mediated cholesterol efflux from macrophages may be an antiatherogenic process. Plasminogen (PLG) is a driver of ABCA1-mediated cholesterol efflux, and its action is inhibited by purified human Lp(a). OBJECTIVE: To determine the effects of Lp(a) in human serum on ABCA1 cholesterol efflux. METHODS: Cholesterol efflux capacity (CEC) was measured with two different cell-culture models using serum from 76 patients with either low (<50 mg/dL) or high (>50 mg/dL) Lp(a) levels. RESULTS: Using cAMP-stimulated J774 macrophages or baby hamster kidney fibroblasts overexpressing human ABCA1, we show that CEC was lower in patients with high Lp(a) levels compared with patients with low levels (-30.6%, P = 0.002 vs -24.1%, P < 0.001, respectively). Total-serum CEC negatively correlated with Lp(a) levels (r = -0.433, P = 0.0007 vs r = -0.505, P = 0.0011, respectively). These negative associations persisted after adjusting for serum cholesterol, age, sex, and statin use in a multiple linear regression model (adjusted R2 = 0.413 or 0.405, respectively) and were strengthened when further adjusting for the interaction between Lp(a) and PLG levels (adjusted R2 = 0.465 and 0.409, respectively). Total-serum and isolated Lp(a) from patients with high Lp(a) inhibited PLG-mediated ABCA1 cholesterol efflux. CONCLUSION: Total-serum CEC is reduced in patients with high Lp(a) levels. This is in part due to the inhibition of PLG-mediated ABCA1 cholesterol efflux by Lp(a). Our findings suggest an atherogenic role for Lp(a) through its ability to inhibit CEC.

AB - CONTEXT: Elevated serum lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular disease risk. ABCA1-mediated cholesterol efflux from macrophages may be an antiatherogenic process. Plasminogen (PLG) is a driver of ABCA1-mediated cholesterol efflux, and its action is inhibited by purified human Lp(a). OBJECTIVE: To determine the effects of Lp(a) in human serum on ABCA1 cholesterol efflux. METHODS: Cholesterol efflux capacity (CEC) was measured with two different cell-culture models using serum from 76 patients with either low (<50 mg/dL) or high (>50 mg/dL) Lp(a) levels. RESULTS: Using cAMP-stimulated J774 macrophages or baby hamster kidney fibroblasts overexpressing human ABCA1, we show that CEC was lower in patients with high Lp(a) levels compared with patients with low levels (-30.6%, P = 0.002 vs -24.1%, P < 0.001, respectively). Total-serum CEC negatively correlated with Lp(a) levels (r = -0.433, P = 0.0007 vs r = -0.505, P = 0.0011, respectively). These negative associations persisted after adjusting for serum cholesterol, age, sex, and statin use in a multiple linear regression model (adjusted R2 = 0.413 or 0.405, respectively) and were strengthened when further adjusting for the interaction between Lp(a) and PLG levels (adjusted R2 = 0.465 and 0.409, respectively). Total-serum and isolated Lp(a) from patients with high Lp(a) inhibited PLG-mediated ABCA1 cholesterol efflux. CONCLUSION: Total-serum CEC is reduced in patients with high Lp(a) levels. This is in part due to the inhibition of PLG-mediated ABCA1 cholesterol efflux by Lp(a). Our findings suggest an atherogenic role for Lp(a) through its ability to inhibit CEC.

UR - http://www.scopus.com/inward/record.url?scp=85071994717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071994717&partnerID=8YFLogxK

U2 - 10.1210/jc.2018-02708

DO - 10.1210/jc.2018-02708

M3 - Article

C2 - 31220285

AN - SCOPUS:85071994717

VL - 104

SP - 4793

EP - 4803

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -